Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta

Kousei Hasegawa, Kyoko Kataoka, Masaru Inoue, Yoshiki Seino, Tsuneo Morishima, Hiroyuki Tanaka

Research output: Contribution to journalArticle

6 Citations (Scopus)


Patients with osteogenesis imperfecta (OI) show various degrees of bone fragility. Nevertheless, details of the mechanisms causing bone fragility remain unclear. We hypothesized that differences in pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules partly contribute to bone fragility of OI. To verify this hypothesis, urinary N and C terminal telopeptides of type I collagen (uNTx and uβCTx, respectively) and urinary hydroxyproline (uHyp) were measured using second morning void urine samples obtained from OI patients and healthy control children. Ratios of uNTx and uβTx to uHyp (uNTx/uHyp and uβCTx/uHyp, respectively) of OI patients and healthy normal control children were analyzed. Ratios of uNTx to uβCTx (uNTx/uβCTx) were also analyzed. In OI patients, uNTx and uβCTx were lower than in healthy control children. Also, uNTx/uHyp and uβCTx/uHyp were significantly lower than in healthy children. Among OI patients, uNTx/uHyp and uNTx/uβCTx of type III OI were significantly lower than of either type I or type IV OI. These results show that pyridinoline cross-link formation is lower than in healthy control children and that pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules might be differently disrupted in OI patients according to the severity of OI.

Original languageEnglish
Pages (from-to)394-399
Number of pages6
JournalJournal of Bone and Mineral Metabolism
Issue number4
Publication statusPublished - Jul 2008



  • Hydroxyproline
  • NTx βCTx
  • Osteogenesis imperfecta
  • Pyridinoline cross-link

ASJC Scopus subject areas

  • Endocrinology

Cite this